These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31149946)

  • 1. Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age.
    Inzaule SC; Jordan MR; Cournil A; Vitoria M; Ravasi G; Cham F; Le LV; Dzangare J; Hamunime N; Mutenda N; Aghokeng A; Bissek A; Billong S; Kaleebu P; Doherty M; Bertagnolio S
    AIDS; 2019 Sep; 33(11):1797-1799. PubMed ID: 31149946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
    Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
    PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
    Dorward J; Lessells R; Drain PK; Naidoo K; de Oliveira T; Pillay Y; Abdool Karim SS; Garrett N
    Lancet HIV; 2018 Jul; 5(7):e400-e404. PubMed ID: 29884404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
    Greig SL; Deeks ED
    Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens.
    Inzaule SC; Hamers RL; Doherty M; Shafer RW; Bertagnolio S; Rinke de Wit TF
    Lancet Infect Dis; 2019 Jul; 19(7):e246-e252. PubMed ID: 30902440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment HIV Drug Resistance Among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens?
    Kouamou V; Mavetera J; Manasa J; Ndhlovu CE; Katzenstein D; McGregor AM
    AIDS Res Hum Retroviruses; 2021 Oct; 37(10):776-783. PubMed ID: 33430681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.
    Phillips AN; Cambiano V; Nakagawa F; Revill P; Jordan MR; Hallett TB; Doherty M; De Luca A; Lundgren JD; Mhangara M; Apollo T; Mellors J; Nichols B; Parikh U; Pillay D; Rinke de Wit T; Sigaloff K; Havlir D; Kuritzkes DR; Pozniak A; van de Vijver D; Vitoria M; Wainberg MA; Raizes E; Bertagnolio S;
    Lancet HIV; 2018 Mar; 5(3):e146-e154. PubMed ID: 29174084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort.
    Capetti AF; Sterrantino G; Cossu MV; Orofino G; Barbarini G; De Socio GV; Di Giambenedetto S; Di Biagio A; Celesia BM; Argenteri B; Rizzardini G
    PLoS One; 2016; 11(10):e0164753. PubMed ID: 27741309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-cycle therapy (5 days on/2 days off) with a lamivudine + dolutegravir regimen in a cohort of virologically suppressed patients with HIV infection.
    Lanzafame M; Lattuada E; Gottardo R; Piacentini D; Be G; Razzaboni E; Cattaneo P; Luise D; Vento S
    Int J Antimicrob Agents; 2021 Mar; 57(3):106290. PubMed ID: 33513407
    [No Abstract]   [Full Text] [Related]  

  • 11. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
    Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
    J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
    Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A;
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
    Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up.
    Rutstein SE; Chen JS; Nelson JAE; Phiri S; Miller WC; Hosseinipour MC
    AIDS Res Ther; 2019 Feb; 16(1):5. PubMed ID: 30795780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
    Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
    AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
    Chouchana L; Beeker N; Treluyer JM
    J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
    Aboud M; Orkin C; Podzamczer D; Bogner JR; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Blair EA; Adkison K; Underwood M; Matthews JE; Wynne B; Vandermeulen K; Gartland M; Smith K
    Lancet HIV; 2019 Sep; 6(9):e576-e587. PubMed ID: 31307948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV.
    Sangaré MN; Baril JG; de Pokomandy A; Laprise C; Deshaies C; Klein M; Thomas R; Tremblay C; Roger M; Pexos C; Greenwald Z; Machouf N; Durand M; Hardy I; Dakouo M; Laporte L; Trottier H
    Medicine (Baltimore); 2020 Nov; 99(47):e23335. PubMed ID: 33217873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
    Braun DL; Scheier T; Ledermann U; Flepp M; Metzner KJ; Böni J; Günthard HF
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33228206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of nucleos(t)ide reverse transcriptase inhibitor resistance on dolutegravir and protease-inhibitor-based regimens in children and adolescents in Kenya.
    Kingwara L; Inzaule SC; Momanyi L; Jordan MR; Nyanya W; Bowen N; Oramisi V; Kiiru JN; Ngugi C
    AIDS; 2022 Mar; 36(4):611-613. PubMed ID: 34923516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.